Fig. 2From: Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysisModeled OS and PFS curves related to the trastuzumab plus chemotherapy group (times in month)Back to article page